{"product_id":"beqalzisonrotoclax-бекалзи-сонротоклакс","title":"BEQALZI(Sonrotoclax)                БЕКАЛЗИ (сонротоклакс)","description":"\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eBEQALZI (sonrotoclax)\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e is a prescription targeted anticancer medicine and a selective \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eB-cell lymphoma 2 (BCL-2) inhibitor\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e. It works by binding to the BCL-2 protein, which can help cancer cells survive, thereby promoting programmed cell death (apoptosis) in malignant cells.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eBEQALZI is indicated for the treatment of \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eadults with relapsed or refractory mantle cell lymphoma (MCL)\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e after at least two previous lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. The indication received accelerated FDA approval in May 2026.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe medicine is available as oral film-coated tablets in \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003e1 mg, 5 mg, 20 mg, and 80 mg\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e strengths. Treatment begins with a gradual dose-escalation schedule before reaching the recommended maintenance dose.\u003c\/span\u003e\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":45376116719659,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/images_2.jpg?v=1789644258","url":"https:\/\/xomeds.com\/products\/beqalzisonrotoclax-%d0%b1%d0%b5%d0%ba%d0%b0%d0%bb%d0%b7%d0%b8-%d1%81%d0%be%d0%bd%d1%80%d0%be%d1%82%d0%be%d0%ba%d0%bb%d0%b0%d0%ba%d1%81","provider":"XOMEDS","version":"1.0","type":"link"}